Creabilis, a clinical stage biotech, has appointed Dr David Roblin chief medical officer. Dr Roblin was most recently Pfizer's senior vice-president, head of research and site head for European R&D. He previously chaired the Research Director's Group of EFPIA, and is currently an advisor at NOCRI in the NHS and a non-executive director of Xceleron.
Creabilis appoints David Roblin CMO
Creabilis, a clinical stage biotech, has appointed Dr David Roblin chief medical officer. Dr Roblin was most recently Pfizer's senior vice-president, head of research and site head for European R&D. He previously chaired the Research Director's Group of EFPIA, and is currently an advisor at NOCRI in the NHS and a non-executive director of Xceleron.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
• By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
• By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
• By
The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.
• By
Private Company Edition: Catalio raised more than $400m for its fourth health care-focused VC fund, while AN Venture Partners raised $200m for Japan and beyond. In VC financings, among a dearth of mega rounds, Neuron23’s $96.5m series D is the largest round in recent weeks.
• By
After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.